Novel therapeutic strategies for androgen-independent prostate cancer: An update

被引：39

作者：

Assikis, VJ ^{[1
]}

Simons, JW ^{[1
]}

机构：

[1] Emory Univ, Winship Canc Inst, Prostate Canc Translat Res Program, Atlanta, GA 30322 USA

来源：

SEMINARS IN ONCOLOGY | 2004年 / 31卷 / 02期

关键词：

D O I：

10.1053/j.seminoncol.2004.02.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：26 / 32

页数：7

共 89 条

[1] Development of the proteasome inhibitor PS-341 [J].

Adams, J .

ONCOLOGIST, 2002, 7 (01) :9-16

[2]

Aghajanian C, 2002, CLIN CANCER RES, V8, P2505

[3]

[Anonymous], 1967, Surg Gynecol Obstet, V124, P1011

[4]

BANDER NH, 2002, P AN M AM SOC CLIN, V21, pA5

[5] Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer [J].

Beer, TM ;

Eilers, KM ;

Garzotto, M ;

Egorin, MJ ;

Lowe, BA ;

Henner, WD .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :123-128

[6] Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer [J].

Berry, W ;

Dakhil, S ;

Modiano, M ;

Gregurich, M ;

Asmar, L .

JOURNAL OF UROLOGY, 2002, 168 (06) :2439-2443

[7]

Boissier S, 2000, CANCER RES, V60, P2949

[8]

Boissier S, 1997, CANCER RES, V57, P3890

[9]

Byar D P, 1988, NCI Monogr, P165

[10]

BYAR DP, 1973, CANCER, V32, P1126, DOI 10.1002/1097-0142(197311)32:5<1126::AID-CNCR2820320518>3.0.CO

← 1 2 3 4 5 6 7 8 9 →